A study to investigate the pharmacokinetics of remibrutinib in CSF in healthy participants.
This research study is investigating a new medication called remibrutinib. Specifically, we want to understand how this drug travels within the body and, crucially, if and how it gets into the fluid surrounding the brain and spinal cord, known as cerebrospinal fluid (CSF). To do this, we'll be working with healthy volunteers. By studying this in healthy people, we can get a clear picture of how the drug behaves without other health conditions complicating the results. This is an early-stage study, meaning it's one of the first times this drug is being looked at in humans. The information we gather will be important for understanding how this drug might be used in the future to treat various conditions, by helping us see if it can reach the places in the body where it needs to work.
At a glance
What is this study about?
This study is an early step in understanding a new medication called remibrutinib. The main goal is to see how this drug behaves once it's in the body, particularly how it reaches the fluid that surrounds your brain and spinal cord. This fluid, called cerebrospinal fluid (CSF), is very important because many conditions affecting the brain and nervous system require medications to reach this area to be effective. By studying healthy people, we can get a clear idea of the drug's journey without other health issues making it more complicated.
Think of it like tracing the route a delivery driver takes. We want to know if the drug can get to its 'delivery destination' in the brain and spinal cord, and how much of it arrives there. This kind of research is vital because it helps doctors and scientists decide if a drug might be useful for treating certain illnesses in the future. It's a foundational step that needs to happen before the drug can be tested in people who are unwell.
This is a 'Phase I' study, which means it's one of the very first times this drug is being given to humans. These early studies are carefully planned and often involve healthy volunteers to ensure safety and gather initial information about how the drug is handled by the body. The insights gained from this study will contribute to the ongoing development of remibrutinib and help determine its potential for future medical uses.
Key takeaways
- This is an early study of a new drug, remibrutinib.
- It aims to see how the drug gets into brain and spinal fluid (CSF).
- Only healthy adults aged 18 and over can participate.
- Participants will receive the drug and have their health monitored.
- There are no direct health benefits for taking part.
- You can stop participating at any time.
Who may be eligible?
This study is looking for healthy adults. To take part, you need to be at least 18 years old, and there is no upper age limit. Both men and women are welcome to participate.
Crucially, you must be in good general health. This means you should not have any ongoing medical conditions that could affect how your body handles the medication or make it unsafe for you to take part. The research team will do medical checks to make sure you're healthy enough for the study.
More specific details about what counts as 'healthy' will be explained by the study team. Things like certain medications you might be taking, or specific results from blood tests, could mean you're not suitable for this particular study, even if you feel well.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy and don't have any major ongoing medical conditions?
- Are you able to attend several clinic visits?
- Are you comfortable with blood tests and potentially a lumbar puncture (spinal tap)?
What does participation involve?
Taking part in this study would involve a series of visits to the clinic. You would receive the study medication, remibrutinib, and then the research team would carefully monitor your health and take samples to see how the drug moves through your body. This would likely involve blood tests and possibly other procedures like a lumbar puncture (spinal tap) to collect samples of the cerebrospinal fluid (CSF).
There would be several check-ups and follow-up appointments after you receive the medication to ensure your well-being and to continue gathering information. The exact number of visits, how long each visit would last, and the total duration of your involvement in the study would be fully explained by the research team before you agree to participate.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is remibrutinib?
Remibrutinib is a new medication that is being tested. This study is an early step to understand how it works in the human body.
Why are you studying it in healthy people?
By studying healthy people, we can get a clear picture of how the drug behaves in the body without other illnesses affecting the results. This helps us understand it better for future use.
What is CSF?
CSF stands for cerebrospinal fluid. It's the clear fluid that surrounds your brain and spinal cord, protecting them and delivering nutrients. We are checking if the drug can reach this fluid.
Will this drug help me if I join the study?
No, this study is not designed to treat a specific illness. It's an early-stage research study to gather information about a new drug. There's no direct health benefit for participants.
Do I get paid for taking part?
Many research studies offer payment for your time and inconvenience. The study team will be able to tell you if this study offers any reimbursement.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.